Olema Pharmaceuticals, Inc. OLMA | NASDAQ
|2026-07-08
Company Overview:
5.9 Year OLMA Performance Metrics:
Build Custom Charts
OLMA Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for OLMA
Based on past 6-year performance, here are OLMA growth metrics:
Share price CAGR of -27.7%
Dividend CAGR of +0%
Using OLMA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| OLMA (DRIP) | OLMA - No DRIP | |
|---|---|---|
| Current Price | $7.00 | $7.00 |
| Start Shares | 1,428.57 | 1,428.57 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 1,428.57 | 1,428.57 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $0.27 | $7.00 |
| Total Dividends | $0 | $0 |
| Final Value | $390 | $10,000 |
NOTE: Above numbers are our estimate based on OLMA's Dividend and Price CAGR over past 6 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Olema Pharmaceuticals, Inc. (OLMA) had its IPO on , and is traded on NASDAQ stock exchange.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with a primary emphasis on breast cancer. The company’s current pipeline centers on palazestrant (OP-1250), an oral estrogen receptor antagonist and selective estrogen receptor degrader being studied for hormone receptor-positive breast cancer, and OP-3136, a KAT6 inhibitor in early clinical development. Olema’s research is built around endocrine-driven cancers and mechanisms of acquired resistance, reflecting a focus on precision oncology approaches for difficult-to-treat disease settings. The company is headquartered in San Francisco, California, with additional operations in Cambridge, Massachusetts. Olema Pharmaceuticals, Inc. plays a specialized role in the biotechnology market as a development-stage oncology company advancing novel medicines for breast cancer and related women’s cancers.
OLMA website: https://olema.com
DCF model unavailable for OLMA — no fundamentals on file (ETFs and funds are not modelable).
